{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Broomfield",
      "state": "CO",
      "country": "United States",
      "classification": "Class III",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "65877",
      "recalling_firm": "Sandoz Incorporated",
      "address_1": "2555 W Midway Blvd",
      "address_2": "N/A",
      "postal_code": "80020-1632",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide",
      "recall_number": "D-854-2013",
      "product_description": "Introvale (levonorgestrel and ethinyl estradiol) tablets, USP, 0.15 mg/0.03 mg, packaged in 91 day regimen per unit carton, 3 Unit Cartons x 91 tablets per box, Rx only, Manufactured by Laboratorios Leon Farma S.A., Spain for Sandoz Inc., Princeton, NJ 08540, NDC 0781-5584-36",
      "product_quantity": "8, 681 unit cartons",
      "reason_for_recall": "Contraceptive tablets out of sequence: Contraceptive tablets out of sequence: Introvale (levonorgestrel and ethinyl estradiol tablets USP 0.15mg/0.03mg) is voluntarily being recalled due to inactive placebo tablets incorrectly placed in Week 9, and active tablets placed in Week 13 on the blister card",
      "recall_initiation_date": "20130807",
      "center_classification_date": "20130808",
      "termination_date": "20140707",
      "report_date": "20130814",
      "code_info": "Lots:  LF01643C, LF01644C, Exp 7/14"
    }
  ]
}